GLY-230
GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction[1][2].
Product Specifications
CAS Number
320777-05-7
UNSPSC
12352005
Target
Amyloid-β
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Metabolic Disease; Neurological Disease
Smiles
OC(CC(C=CC=C1)=C1NC2=CC(Cl)=CC=C2)=O
Molecular Formula
C14H12ClNO2
Molecular Weight
261.70
References & Citations
[1]Kennedy L, et al. Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. Am J Nephrol. 2010;31 (2) :110-6.|[2]Cohen MP, et al. Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate. Clin Exp Pharmacol Physiol. 2009 Nov;36 (11) :1099-103.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740253-100 1x 100 µL
Cytokeratin, LMW (AE-1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680276-100 1x 100 µL
TAG-72 / CA72.4 (B72.3), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040637-100 1x 100 µL
Renal Cell Carcinoma (Carbonic Anhydrase IX) (PN-15), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040823-100 1x 100 µL
P21 / WAF1 (CIP1/823), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940226-100 1x 100 µL
Pmel17 / gp100 / SILV (NKI-beteb), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details